

Simone I Strasser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/657465/publications.pdf>

Version: 2024-02-01

121
papers

7,251
citations

101543

36
h-index

58581

82
g-index

127
all docs

127
docs citations

127
times ranked

9022
citing authors

#	ARTICLE	IF	CITATIONS
1	Turning the Tide on Hepatitis C Virus-Related Liver Transplantation: The Return on Investment in Hepatitis C Virus Treatment in Australia and New Zealand. <i>Liver Transplantation</i> , 2022, 28, 236-246.	2.4	3
2	Drug-induced liver injury from herbal and dietary supplements: a problem in the East and West alike. <i>Hepatology International</i> , 2022, , 1.	4.2	0
3	A multicenter, observational, phase 4 study (STELLAR) to evaluate the safety and tolerability of lenvatinib (LEN) in patients with advanced or unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS485-TPS485.	1.6	1
4	Australian consensus recommendations for the management of hepatitis B. <i>Medical Journal of Australia</i> , 2022, 216, 478-486.	1.7	15
5	Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension. <i>Infectious Diseases and Therapy</i> , 2022, 11, 913-924.	4.0	1
6	Is it safe to expand the indications for split liver transplantation in adults? A single-centre analysis of 155 in-situ splits. <i>Clinical Transplantation</i> , 2022, , e14673.	1.6	5
7	Stopping nucleot(s)ide analogues in non-cirrhotic <scp>HBeAg</scp>-negative chronic hepatitis B patients: <scp>HBsAg</scp> loss at 96% weeks is associated with low baseline <scp>HBsAg</scp> levels. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 310-320.	3.7	16
8	Expansion of Liver Transplantation Criteria for Hepatocellular Carcinoma from Milan to UCSF in Australia and New Zealand and Justification for Metroticket 2.0. <i>Cancers</i> , 2022, 14, 2777.	3.7	4
9	Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up. <i>BMC Gastroenterology</i> , 2022, 22, .	2.0	2
10	Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics. <i>Clinical Infectious Diseases</i> , 2021, 73, e3288-e3295.	5.8	21
11	Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. <i>Hepatology</i> , 2021, 73, 625-643.	7.3	156
12	Palliative care in hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 618-628.	2.8	29
13	Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. <i>Medical Journal of Australia</i> , 2021, 214, 475-483.	1.7	36
14	Palliative medicine referrals for hepatocellular carcinoma: a national survey of gastroenterologists. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjspcare-2020-002807.	1.6	2
15	Beware of Portal Vein Thrombosis After Laparoscopic Sleeve Gastrectomy in Liver Transplant Recipients. <i>Liver Transplantation</i> , 2021, 27, 1066-1067.	2.4	3
16	Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2021, 5, 1201-1211.	4.3	16
17	Drug-induced liver injury in Australia, 2009-2020: the increasing proportion of non-paracetamol cases linked with herbal and dietary supplements. <i>Medical Journal of Australia</i> , 2021, 215, 261-268.	1.7	18
18	APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. <i>Hepatology International</i> , 2021, 15, 1031-1048.	4.2	56

#	ARTICLE	IF	CITATIONS
19	Immune checkpoint inhibitor-related hepatotoxicity: A review. <i>World Journal of Gastroenterology</i> , 2021, 27, 5376-5391.	3.3	52
20	Impact of COVID-19 on Hepatocellular Carcinoma Management: A Multicountry and Region Study. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1159-1167.	3.7	21
21	Australian recommendations for the management of hepatocellular carcinoma. <i>Medical Journal of Australia</i> , 2021, 215, 334.	1.7	1
22	Therapeutic vaccine BR11-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study. <i>JHEP Reports</i> , 2021, 3, 100361.	4.9	24
23	Depot Pure GnRH Antagonist for Long-term Treatment of Ovarian Hyperthecosis Monitored by Multiteroid LCMS Profiling. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab167.	0.2	2
24	Prevalence and outcomes of <i>Clostridioides difficile</i> infection in liver transplant recipients. <i>Transplant Infectious Disease</i> , 2021, , e13758.	1.7	3
25	Hepatobiliary and Pancreatic: Diaphragmatic paralysis after transarterial chemoembolization of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 181-181.	2.8	1
26	mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. <i>Annals of Surgery</i> , 2020, 272, 855-862.	4.2	85
27	Nonalcoholic fatty liver disease burden: Australia, 2019â€“2030. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1628-1635.	2.8	68
28	Differential Impact of Extended Criteria Donors After Brain Death or Circulatory Death in Adult Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 1603-1617.	2.4	21
29	Efficacy and safety profile of calcineurin inhibitor salvage therapy in autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1309-1317.	1.5	5
30	Emerging role of endoscopic ultrasound-guided liver biopsy. <i>Gut</i> , 2020, , gutjnl-2020-322704.	12.1	3
31	Epidemiology and risk factors for invasive fungal disease in liver transplant recipients in a tertiary transplant center. <i>Transplant Infectious Disease</i> , 2020, 22, e13361.	1.7	15
32	Impact of Having a Planned Additional Operation at Time of Liver Transplant on Graft and Patient Outcomes. <i>Journal of Clinical Medicine</i> , 2020, 9, 608.	2.4	1
33	The impact of the COVIDâ€™19 pandemic on gastroenterology trainees in Australia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1841-1842.	2.8	5
34	BK Nephropathy as a Cause of Renal Dysfunction in an ABO-incompatible Liver Transplant Patient. <i>Transplantation</i> , 2020, 104, e83-e84.	1.0	3
35	Reply to â€™Comments on the Editor Re: The Relationship of Obesity, Nutritional Status and Muscle Wasting in Patients Assessed for Liver Transplantation, <i>Nutrients</i> 2019, 11, 2097.â€™ <i>Nutrients</i> , 2020, 12, 869.	4.1	0
36	Management and Outcomes of Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder in the PET/CT Era: A Multicentre Study from the Australasian Lymphoma Alliance. <i>Blood</i> , 2020, 136, 36-38.	1.4	0

#	ARTICLE	IF	CITATIONS
37	IDDF2020-ABS-0162â€¦Trends in hospitalised drug-induced liver injury from 2009 to 2019 â€“ the rise of non-prescription medications. , 2020, , .		0
38	IDDF2020-ABS-0176â€¦Clinician experience and attitudes to palliative care in patients with HCC â€“ an Australia-wide survey. , 2020, , .		0
39	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut, 2019, 68, 1065-1075.	12.1	195
40	Supplementation with Synbiotics and/or Branched Chain Amino Acids in Hepatic Encephalopathy: A Pilot Randomised Placebo-Controlled Clinical Study. Nutrients, 2019, 11, 1810.	4.1	30
41	Clinical Cases in Hepatitis: Towards improving liver disease management in Australia. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 5-15.	2.8	1
42	Letter: elderly AIH patients-an important subgroup. Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 615-615.	3.7	0
43	Management of Patients With Erythropoietic Protoporphyrinâ€“Related Progressive Liver Disease. Liver Transplantation, 2019, 25, 1620-1633.	2.4	17
44	The Relationship of Obesity, Nutritional Status and Muscle Wasting in Patients Assessed for Liver Transplantation. Nutrients, 2019, 11, 2097.	4.1	25
45	Hepatobiliary and Pancreatic: Kasabachâ€“Merritt syndrome in adult. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1675-1675.	2.8	0
46	Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement. Medical Journal of Australia, 2019, 210, 462-468.	1.7	13
47	Surface antigen negative hepatitis B infection: the importance of screening before B cellâ€“depleting therapy. Medical Journal of Australia, 2019, 210, 442.	1.7	0
48	Editorial: tailoring mycophenolate mofetil rescue therapy for success in autoimmune hepatitis-authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 1450-1451.	3.7	0
49	Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels. Alimentary Pharmacology and Therapeutics, 2019, 49, 1314-1322.	3.7	21
50	IDDF2019-ABS-0196â€¦Long term outcomes of utilizing donation after circulatory death grafts in liver transplantation â€“ an australian 12-year cohort study. , 2019, , .		0
51	IDDF2019-ABS-0220â€¦Long-term outcomes of utilizing extended criteria deceased donors in liver transplantation â€“ an australian 12-year cohort study. , 2019, , .		0
52	Immunity to Vaccine-preventable Viral Infections in Australians Being Evaluated for Liver Transplantation. Transplantation, 2019, 103, 2318-2322.	1.0	10
53	Detection of Hepatitis C Antibodies Without Viral Transmission in Hepatitis C-Negative Recipients Receiving Kidneys From Hepatitis C-Positive Donors Treated With Direct-Acting Antiviral Therapy. Transplantation, 2018, 102, e121-e122.	1.0	5
54	The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. Journal of Gastroenterology, 2018, 53, 679-688.	5.1	43

#	ARTICLE	IF	CITATIONS
55	Gastrointestinal: Knot the intent. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1431-1431.	2.8	1
56	High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1 patients without cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 293-300.	3.7	127
57	Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 268-277.	4.4	39
58	Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens. <i>Liver International</i> , 2018, 38, 821-833.	3.9	20
59	Sclerosing peritonitis post liver transplantation: a rare condition where surgery is an important treatment option. <i>ANZ Journal of Surgery</i> , 2018, 88, E424-E428.	0.7	0
60	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 940-952.	10.7	1,816
61	Frailty in advanced liver disease. <i>Liver International</i> , 2018, 38, 2117-2128.	3.9	73
62	Design of the Prospective Real-world Outcomes Study of hepatic encephalopathy Patients' Experience on Rifaximin-± (PROSPER): an observational study among 550 patients. <i>Hepatology, Medicine and Policy</i> , 2018, 3, 4.	1.7	5
63	Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study. <i>Hepatology</i> , 2017, 66, 736-745.	7.3	67
64	Real-World Efficacy and Safety of Ritonavir-Boosted Paritaprevir, Ombitasvir, Dasabuvir ± Ribavirin for Hepatitis C Genotype 1 – Final Results of the REVITAL Study. <i>Antiviral Therapy</i> , 2017, 22, 699-710.	1.0	11
65	Disease Reversibility in Patients With Post-Hepatitis C Cirrhosis. <i>Transplantation</i> , 2017, 101, 916-923.	1.0	19
66	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. <i>Transplantation</i> , 2017, 101, 945-955.	1.0	76
67	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. <i>Transplantation</i> , 2017, 101, 956-967.	1.0	44
68	Epidemiology and outcomes of primary sclerosing cholangitis with and without inflammatory bowel disease in an Australian cohort. <i>Liver International</i> , 2017, 37, 442-448.	3.9	22
69	Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed <sc>LAM</sc>/<sc>ADV</sc> therapy. <i>Liver International</i> , 2017, 37, 827-835.	3.9	13
70	Interactions between primary sclerosing cholangitis and inflammatory bowel disease: implications in the adult liver transplant setting. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 949-960.	3.0	5
71	Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. <i>New England Journal of Medicine</i> , 2017, 376, 2134-2146.	27.0	467
72	An update on the pathophysiology and management of polycystic liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 569-581.	3.0	16

#	ARTICLE	IF	CITATIONS
73	Longterm outcome of the liver graft: A clinician's perspectiveâ€”recurrent disease, the universal shifting. <i>Liver Transplantation</i> , 2017, 23, S64-S69.	2.4	0
74	Fever and Pancytopenia in a Liver Transplant Recipient: Going Against the Rules of Occam's Razor. <i>Transplantation Direct</i> , 2017, 3, e169.	1.6	1
75	Managing hepatitis C in general practice. <i>Australian Prescriber</i> , 2017, 40, 64-69.	1.0	7
76	Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2017, 23, 2763.	3.3	6
77	Prevalence and outcomes of pancreatic cystic neoplasms in liver transplant recipients. <i>World Journal of Gastroenterology</i> , 2017, 23, 8526-8532.	3.3	8
78	A survey of Sydney general practitioners' management of patients with chronic hepatitis B. <i>Medical Journal of Australia</i> , 2016, 204, 74-74.	1.7	4
79	Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0155800.	2.5	54
80	The increasing burden of potentially preventable liver disease among adult liver transplant recipients: A comparative analysis of liver transplant indication by era in Australia and New Zealand. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 434-441.	2.8	14
81	A prospective audit of preprocedural fasting practices on a transplant ward: when fasting becomes starving. <i>Journal of Clinical Nursing</i> , 2016, 25, 829-835.	3.0	5
82	Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 979-985.	1.5	14
83	A randomized, controlled study of peginterferon lambda-1a/ribavirin±daclatasvir for hepatitis C virus genotype 2 or 3. <i>SpringerPlus</i> , 2016, 5, 1365.	1.2	8
84	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , 2016, 375, 631-643.	27.0	817
85	Cryptococcal osteomyelitis of the skull in a liver transplant patient. <i>Transplant Infectious Disease</i> , 2016, 18, 954-956.	1.7	8
86	Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma. <i>Transplantation</i> , 2016, 100, 116-125.	1.0	339
87	Combination of Tenofovir Disoproxil Fumarate and Peginterferon Î±-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2016, 150, 134-144.e10.	1.3	284
88	Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders. <i>Gut</i> , 2016, 65, 340-350.	12.1	62
89	Efficacy and Safety of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Virus Infection and Inherited Blood Disorders: Final Data from the C-Edge Ibd Study. <i>Blood</i> , 2016, 128, 1303-1303.	1.4	1
90	Hepatic artery stenosis after liver transplantation: Is endovascular treatment always necessary?. <i>Liver Transplantation</i> , 2015, 21, 162-168.	2.4	42

#	ARTICLE	IF	CITATIONS
91	Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection. <i>Annals of Internal Medicine</i> , 2015, 163, 809-817.	3.9	79
92	Washout of hepatocellular carcinoma on portal venous phase of multidetector computed tomography in a pre-transplant population. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2015, 59, 673-680.	1.8	6
93	Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. <i>PLoS ONE</i> , 2015, 10, e0138503.	2.5	3
94	Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection. <i>Gastroenterology</i> , 2015, 148, 355-366.e1.	1.3	49
95	Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program. <i>Journal of Hepatology</i> , 2014, 61, 976-983.	3.7	25
96	Tenofovir-Associated Fanconi Syndrome in Patients with Chronic Hepatitis B Monoinfection. <i>Antiviral Therapy</i> , 2013, 18, 945-948.	1.0	66
97	<i>Amanita phalloides</i> poisoning and treatment with silibinin in the Australian Capital Territory and New South Wales. <i>Medical Journal of Australia</i> , 2013, 198, 43-47.	1.7	34
98	Drugs in Development for the Treatment of Chronic Hepatitis B. <i>Current Hepatitis Reports</i> , 2012, 11, 111-118.	0.3	4
99	Grade of deceased donor liver macrovesicular steatosis impacts graft and recipient outcomes more than the Donor Risk Index. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 540-546.	2.8	143
100	Predictors of deferral of treatment for hepatitis C infection in Australian clinics. <i>Medical Journal of Australia</i> , 2011, 194, 398-402.	1.7	42
101	Feasibility of conducting a randomized control trial for liver cancer screening: Is a randomized controlled trial for liver cancer screening feasible or still needed?. <i>Hepatology</i> , 2011, 54, 1998-2004.	7.3	125
102	An unusual renal manifestation of chronic HBV infection. <i>CKJ: Clinical Kidney Journal</i> , 2010, 3, 360-362.	2.9	0
103	Donor and recipient selection leads to good patient and graft outcomes for right lobe split transplantation versus whole graft liver transplantation in adult recipients. <i>Liver Transplantation</i> , 2009, 15, 1586-1593.	2.4	22
104	Poorer survival in patients whose explanted hepatocellular carcinoma (HCC) exceeds Milan or UCSF Criteria. An analysis of liver transplantation in HCC in Australia and New Zealand. <i>Hpb</i> , 2009, 11, 81-89.	0.3	29
105	A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. <i>Hepatology</i> , 2008, 48, 1460-1466.	7.3	149
106	Effect of Ascites on Bone Density Measurement in Cirrhosis. <i>Journal of Clinical Densitometry</i> , 2007, 10, 391-394.	1.2	22
107	Combination adefovir/lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1500-1505.	2.8	15
108	Outcome of patients with hepatocellular carcinoma referred to a tertiary centre with availability of multiple treatment options including cadaveric liver transplantation. <i>Liver International</i> , 2007, 27, 1240-1248.	3.9	22

#	ARTICLE	IF	CITATIONS
109	Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. <i>Clinical Transplantation</i> , 2006, 20, 369-373.	1.6	46
110	Severe autoimmune hepatitis first presenting in the early post partum period. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 622-624.	4.4	53
111	The Direct Cost of Managing Patients With Chronic Hepatitis B Infection in Australia. <i>Journal of Clinical Gastroenterology</i> , 2004, 38, S187-S192.	2.2	19
112	Recombinant activated factor VII for the treatment of life-threatening haemorrhage. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 713-717.	1.0	81
113	Severe Gastrointestinal Bleeding After Hematopoietic Cell Transplantation, 1987-1997: Incidence, Causes, and Outcome. <i>American Journal of Gastroenterology</i> , 2001, 96, 385-393.	0.4	47
114	Chronic graft-versus-host disease of the liver: Presentation as an acute hepatitis. <i>Hepatology</i> , 2000, 32, 1265-1271.	7.3	114
115	Hepatitis C virus infection and bone marrow transplantation: A cohort study with 10-year follow-up. <i>Hepatology</i> , 1999, 29, 1893-1899.	7.3	157
116	CHOLESTASIS AFTER HEMATOPOIETIC CELL TRANSPLANTATION. <i>Clinics in Liver Disease</i> , 1999, 3, 651-668.	2.1	20
117	Regulation of uridine diphosphate glucuronosyltransferase during the acute phase response. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 88-94.	2.8	24
118	Iron overload in bone marrow transplant recipients. <i>Bone Marrow Transplantation</i> , 1998, 22, 167-173.	2.4	88
119	Sex hormones differentially regulate isoforms of UDP-glucuronosyltransferase. <i>Pharmaceutical Research</i> , 1997, 14, 1115-1121.	3.5	20
120	Hypothalamic-pituitary-testicular function in end-stage non-alcoholic liver disease before and after liver transplantation. <i>Clinical Endocrinology</i> , 1995, 43, 331-337.	2.4	82
121	Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. <i>Journal of Hepatology</i> , 1995, 23, 487-496.	3.7	109